CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics (CRSP) incurred a third-quarter 2024 loss of $1.01 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.33. In the year-ago period, the company incurred a loss of $1.41 per share.Total revenues, though negligible, were entirely from grant revenues, which amounted to $0.6 million in the quarter. The reported figure significantly missed the Zacks Consensus Estimate of $6.4 million. CRSP did not generate revenues during the year-ago period.More on CRSP’s EarningsR ...